MedPath

Long-term Safety and Efficacy of Deucravacitinib in Participants with Crohn's Disease or Ulcerative Colitis (IM011-077)

Completed
Conditions
Moderate to Severe Crohn's Disease or Moderate to Severe Ulcerative Colitis
Registration Number
jRCT2031210637
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
15
Inclusion Criteria

Previously completed OLE treatment in 1 of the parent CD or UC studies

Exclusion Criteria

Any disease or medical condition that, in the opinion of the investigator, would make the participant unsuitable for this study, would interfere with the interpretation of participant safety or study results, or is considered unsuitable by the investigator for any other reason.

Study & Design

Study Type
Interventional
Study Design
single assignment
Primary Outcome Measures
NameTimeMethod
-

To assess the safety and tolerability of long-term use of BMS-986165(Deucravacitinib)

Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.